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Abstract
Steroid hormones play a central role in the maintenance and progression of prostate 
cancer. The androgen receptor is the primary driver of tumor cell proliferation and 
is activated by the androgens testosterone and 5α-dihydrotestosterone. Inhibition of 
this pathway through medical or surgical castration improves survival in the majority 
of advanced prostate cancer patients. However, conversion of adrenal androgen 
precursors and alternative steroidogenic pathways have been found to contribute to 
tumor progression and resistance to treatment. The emergence of highly accurate 
detection methods allows us to study steroidogenic mechanisms in more detail, even 
after treatment with potent steroidogenic inhibitors such as the CYP17A1 inhibitor 
abiraterone. A clear overview of steroid hormone levels in patients throughout the local, 
metastatic and castration-resistant stages of prostate cancer and treatment modalities 
is key toward a better understanding of their role in tumor progression and treatment 
resistance. In this review, we summarize the currently available data on steroid hormones 
that have been implicated in the various stages of prostate cancer. Additionally, this 
review addresses the implications of these findings, highlights important studies in this 
field and identifies current gaps in literature.
Introduction
Prostate cancer (PC) is the most prevalent form of 
cancer, with the exception of non-melanoma skin 
cancers, in men in Western countries with an estimated 
677.473 new cases in Europe and North America in 
2014 (Forman & Ferlay 2014). In addition, it is a major 
contributor to cancer-related mortality in these regions 
with an estimated 126.430 prostate cancer-related deaths, 
ranking third in men after lung and colorectal cancers 
(Forman & Ferlay 2014). PC presents relatively late in 
life, after a median of 68  years and is often discovered 
during routine examinations or upon examination of 
urogenital discomfort. Early stage, localized PC can be 
treated with curative intent by prostatectomy or localized 
radiotherapy (Attard et al. 2016). Active surveillance may 
be employed in some cases if immediate treatment is not 
deemed necessary or beneficial, for example in patients 
with low risk (Klotz & Emberton 2014, Hamdy et al. 2016). 
Metastatic prostate cancer is very difficult to treat due to 
its tendency to metastasize to the bone (Ye et al. 2007). 
As such, only palliative treatment options exist.
The androgen receptor (AR) is the main driver of 
prostate cancer proliferation and is primarily activated 
by the androgenic steroid hormones testosterone and 
5α-dihydrotestosterone (DHT). Androgens are derived 
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from cholesterol in a multi-step process (Fig.  1) that 
primarily involves the testes, although androgens 
precursors are also secreted from the zona reticularis of the 
adrenal cortex. In the prostate, circulating testosterone 
is converted by 5α-reductase (SRD5A1 and 2) into DHT, 
which has higher affinity and improved retention at the 
AR compared to testosterone (Askew et  al. 2007). Upon 
activation, the AR dissociates from its chaperone heat 
Figure 1
Overview of steroidogenesis leading to the production of androgens, estrogens, mineralocorticoids and glucocorticoids. The classical pathway produces 
DHT through conversion of DHEA, androstenedione and testosterone. The backdoor pathway of DHT synthesis completely bypasses canonical androgen 
synthesis and instead involves 5α-reduced conversion products ultimately leading to the production of androsterone or androstanediol as precursors for 
DHT. An alternative pathway produces DHT with androstanedione as intermediary rather than testosterone. Black arrows depict conversions steps with 
the responsible enzymes listed in red. The 11-oxygenated androgen synthesis pathway is listed, starting with the conversion of androstenedione to 
11-hydroxy-androstenedione. DHEA, dehydroepiandrosterone; DHEAS, dehydroepiandrosterone-sulfate; DHT, 5α-dihydrotestosterone; DOC, 
deoxycorticosterone.
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shock protein 90 (HSP90) and translocates to the nucleus 
where it acts as a transcription factor (Trepel et al. 2010). 
The AR subsequently drives the expression of oncogenes 
causing proliferation of PC cells.
Androgen deprivation therapy (ADT) through medical 
castration with or without anti-androgens is the mainstay 
therapy for advanced prostate cancer (Perlmutter & Lepor 
2007). First-line ADT typically consists of treatment with 
gonadotropin-releasing hormone (GnRH) agonists or 
antagonists reducing the secretion of luteinizing hormone 
(LH) and consequently preventing the production of 
testosterone in testicular Leydig cells. GnRH agonists 
initially cause an LH surge followed by downregulation 
of the GnRH receptor and sustained suppression of LH 
levels, while GnRH antagonists cause an immediate 
reduction of LH secretion. This treatment improves 
survival in most men, but resistance to treatment typically 
occurs within 2–3 years. This next stage of the disease is 
termed castration-resistant prostate cancer (CRPC) and is 
accompanied by a poor overall survival of 16–18 months 
on average (Harris et al. 2009).
CRPC can be treated with docetaxel chemotherapy 
(Tannock et al. 2004), the second-line anti-androgen axis 
drugs abiraterone and enzalutamide, but resistance to 
these drugs typically occurs within 6–18  months (Ryan 
et  al. 2013b, Beer et  al. 2014). Compared to first-line 
ADT, abiraterone causes a more complete suppression of 
androgen synthesis by inhibiting cytochrome P450 (CYP) 
17-hydroxylase/17,20-lyase (CYP17A1), a protein that 
catalyzes key steps in the production of androgens (Fig. 1). 
As a result, the production of the androgen precursors 
dehydroepiandrosterone (DHEA) and androstenedione 
and subsequently that of potent androgens is inhibited. 
Hence, abiraterone also suppresses adrenal androgen 
precursor synthesis, while first-line ADT only suppresses 
gonadal androgen synthesis. Abiraterone has to be 
co-administered with glucocorticoids as CYP17A1 
inhibition results in enhanced ACTH-stimulation of 
the adrenal, which, in combination with the CYP17A1 
block, causes significant accumulation of steroids with 
mineralocorticoid activity and consequently hypokalemia 
and hypertension (Pia et  al. 2013). Interestingly, 
abiraterone and its metabolite Δ4-abiraterone also act as 
inhibitors of 3β-hydroxysteroid dehydrogenase (3β-HSD) 
and as AR antagonists, respectively (Li et al. 2012, 2015).
Enzalutamide is a recently developed and potent 
antagonist of the androgen receptor. It displaces DHT 
at lower concentrations than earlier anti-androgens 
such as biculatamide (Tran et  al. 2009). Compared to 
flutamide and biculatamide, it shows less agonistic 
properties in AR-mutated or AR-overexpressing settings 
(Tran et al. 2009, Korpal et al. 2013), which is critical as 
one of the mechanisms sustaining PC growth is through 
continuously evolving AR mutations in the cancer cells. 
The clinical benefits shown in phase III randomized clinical 
trials with enzalutamide and abiraterone suggest that AR 
activation is still an essential component of CRPC growth 
and progression, both before as well as after docetaxel 
chemotherapy (de Bono et al. 2011, Scher et al. 2012, Ryan 
et  al. 2013b, Beer et  al. 2014). Continued expression of 
AR-regulated genes such as prostate-specific antigen (PSA) 
during second-line anti-androgen axis treatment supports 
this hypothesis (Conteduca et al. 2016).
Several mechanisms for continued AR activation in the 
presence of low circulating levels of androgenic steroids 
have been proposed. Key observations have come from 
studies looking at continued relevance of the AR (Chen 
et al. 2004a) and residual androgen presence in PC tissues 
(Mohler et  al. 2004). Conversion of circulating adrenal 
androgens androstenedione, DHEA and its sulfated form 
(DHEAS) into testosterone and DHT through elevation of 
17β-hydroxysteroid dehydrogenase (HSD) has been shown 
to occur in CRPC (Stanbrough et al. 2006, Hofland et al. 
2010, Kumagai et al. 2013). It has been suggested that, in 
the absence of testis-derived testosterone, expression of 
steroidogenic enzymes may allow tumor cells to generate 
androgens themselves (Locke et  al. 2008, Montgomery 
et  al. 2008, Ishizaki et  al. 2013). However, in what way 
de novo synthesis of androgens contributes to the CRPC 
resistance phenotype in the clinical setting has not yet 
been determined.
Alternatively, additional DHT synthesis pathways 
have been proposed that completely bypass the classic 
androgen synthesis pathway via testosterone (Fig.  1). 
Other mechanisms involved in resistance to castration 
include AR ligand promiscuity due to mutations, 
allowing the AR to become activated by a variety of 
steroid hormones (Duff & McEwan 2005). As such, 
steroid hormones other than testosterone and DHT may 
be of great clinical interest considering their suspected 
involvement in resistance mechanisms. Also, the role 
of steroidal ligands for activation of (hetero)dimers of 
various splice variants of the AR constitutes an expanding 
field of interest (Cao et al. 2016).
Given the crucial role of androgenic hormones 
during the disease evolution, the purpose of this review 
is to create an overview of variations in circulating steroid 
concentrations throughout different stages and treatment 
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modalities of PC. While efforts have been undertaken to 
include data on all stages and modalities, most findings 
in literature report serum steroids levels in the treatment-
naïve stage of prostate cancer, after treatment with 
androgen deprivation therapy and/or abiraterone with 
prednisone. Thus, we will primarily discuss those stages 
and treatment modalities.
This overview summarizes our understanding of 
steroid fluxes and how they may relate to prostate cancer 
progression. As the AR continues to constitute a key driving 
factor of PC growth, detailed knowledge of all relevant 
ligands are of crucial importance. This could also help to 
identify circulating steroid levels for clinical use, i.e. for 
prediction of response to anti-hormonal therapy. Finally, 
gaps in currently available data and future prospects will 
be identified.
Steroidogenesis
Steroid hormones are derived from cholesterol in a 
sequential process involving several steroidogenic 
enzymes (Fig. 1). First, the cholesterol side chain is cleaved 
by the mitochondrial protein cytochrome P450 side chain 
cleavage enzyme CYP11A1 to generate the common steroid 
precursor pregnenolone (Miller & Auchus 2011, Chien 
et al. 2017). This reaction occurs primarily in the gonads 
and adrenal cortex after stimulation with gonadotrophins 
and adrenocorticotrophic hormone (ACTH), respectively 
(Payne 1990, Sewer & Waterman 2003). Pregnenolone can 
be converted by 3β-HSD type 1 or 2 (encoded by HSD3B1 
and HSD3B2) to progesterone, which serves an important 
function in female reproduction. Progesterone in turn 
can by catalyzed by steroid 21-hydroxylase (CYP21A2) 
and 11β-hydroxylase (CYP11B1 and CYP11B2) to 
generate mineralocorticoids (Ryan & Engel 1957, Miller 
& Auchus 2011). Alternatively, both pregnenolone and 
progesterone can be hydroxylated by CYP17A1 to generate 
17OH-pregnenolone and 17OH-progesterone, respectively 
(Miller & Auchus 2011). The glucocorticoid cortisol can 
be synthesized from 17OH-progesterone catalyzed by 
CYP21A2 and CYP11B1. DHEA can be produced from 
17OH-pregnenolone through the 17,20-lyase activity of 
CYP17A1 in conjunction with cytochrome b5 (CYB5A) 
(Kok et al. 2010). In the adrenal gland, DHEA is sulfated 
by DHEA sulfotransferase (SULT2A1) to DHEAS, and 
impairment of DHEA sulfation causes increased generation 
of active androgens (Noordam et al. 2009, Oostdijk et al. 
2015). Dehydrogenization and isomerization of DHEA by 
3β-HSD produces the androgen and estrogen precursor 
androstenedione. The production of testosterone 
from androstenedione is catalyzed by HSD17B3 in the 
testes (Lin et al. 1997, Miller & Auchus 2011) and aldo-
ketoreductase family 1 member C3 (AKR1C3, also known 
as HSD17B5) in other tissues. Increased expression of 
AKR1C3 has been detected in advanced CRPC (Hofland 
et  al. 2010), and recently, it has been shown to confer 
resistance to androgen pathway-targeting therapies (Liu 
et  al. 2015, 2017). A final conversion step catalyzed 
by the two 5-alpha reductase isozymes (SRD5A1 and 
SRD5A2) in the prostate generates DHT, which has the 
highest AR-binding affinity of all endogenous androgens 
(Gao et  al. 2005). Alternatively, androstenedione and 
testosterone can be aromatized by CYP19A1 to form 
the estrogenic steroid hormones estrone and estradiol, 
respectively (Rahman et al. 2016).
In recent years, alternative DHT synthesis pathways 
have been proposed to contribute to intratumoral DHT 
while bypassing testosterone (Chang et al. 2011, Penning 
2014). Especially in patients treated with the CYP17A1 
inhibitor abiraterone, it is thought that accumulation of 
steroids upstream of CYP17A1 (Attard et  al. 2008) may 
contribute to the production of alternative pathway 
steroids such as 5α-progesterone and allopregnanolone. 
Thus, changes in steroid serum levels may have clinical 
consequences for treatment resistance that we are not 
fully aware of yet.
Steroid hormone levels throughout the 
different stages of prostate cancer
Several different units of measurements are used 
in literature to report serum steroid concentrations 
(e.g. ng/mL, ng/dL, nM). To facilitate the comparison of 
findings from different publications and between different 
steroids we have chosen to summarize all data in this 
article in molar concentrations. An overview of conversion 
factors can be found in Table 1. Unless specified, steroid 
concentrations of controls were obtained from healthy 
individuals in the relevant age range that resembles those 
at risk or suffering from prostate cancer (>50 years old), 
since steroid levels can vary significantly by age (Belanger 
et  al. 1994). Data on circulating levels of the relevant 
steroid hormones have been summarized in Fig.  2 and 
Supplementary Table  1 (see section on supplementary 
data given at the end of this article).
The modality used to measure steroid levels also 
differs between studies. The recent advance of novel liquid 
chromatography tandem mass spectrometry (LC–MS/MS) 
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techniques in the last decade has significantly improved 
the field of steroid hormone estimations. Compared 
to radioimmunoassays (RIA) and chemiluminescence 
immunoassays, LC–MS/MS can reach a lower limit of 
quantification, lacks cross-reactivity and can perform 
multi-steroid measurements in a single run. This 
review includes results from both mass spectrometry- 
and antibody-based assays to give a broad overview 
of the available data, although LC–MS/MS data are 
generally preferred.
Testosterone
Targeting testosterone synthesis has been central to 
prostate cancer treatment ever since the discovery of the 
effects of castration on prostate cancer by Huggins, more 
than 70 years ago, was awarded with the Nobel Prize. As 
such, many studies have evaluated testosterone levels in 
order to determine treatment efficacy, predict cancer or 
progression risk or to study molecular pathways related 
to AR signaling. Importantly, testosterone shows a diurnal 
rhythm with peak levels in the morning and nadir at 
night, although the circadian amplitude dissipates with 
increasing age (Bremner et al. 1983, Diver et al. 2003).
Serum testosterone concentrations in healthy controls 
are reported with high consistency throughout multiple 
larger studies, which included >1000 subjects (Belanger 
et al. 1994, Severi et al. 2006, Crawford et al. 2007, Daniels 
et al. 2010, Mondul et al. 2010, Tsilidis et al. 2015, Schenk 
et al. 2016) as well as in a large meta-analysis of 18 studies 
by the Endogenous Hormones and Prostate Cancer 
Collaborative group (EHPCCG) (Endogenous Hormones 
and Prostate Cancer Collaborative Group 2008). These 
data are in line with data obtained from LC–MS/MS 
measurements in another study (Yamashita et  al. 2009). 
The reported median testosterone concentrations in 
these studies lie between 10 and 24 nM and interquartile 
range (IQR) values varied from 8.7 to 29.9 nM for the 
control populations (Endogenous Hormones and Prostate 
Cancer Collaborative Group 2008). Several smaller studies 
reported serum testosterone mean values that fall securely 
within this ‘normal’ range (Gann et al. 1996, Chen et al. 
2003, Trifiro et al. 2010).
Relevant confounders of serum testosterone levels are 
age, body mass index (BMI) and chronic illness (Wu et al. 
2008). Total serum testosterone declines by approximately 
1 nM per decade (Harman et  al. 2001). Taking the 
concomitant rise of sex hormone-binding globulin (SHBG) 
into account, the decline in circulating levels of unbound 
or free testosterone is even more pronounced with age. 
Through multifactorial causes obesity is also associated 
with lower levels of total testosterone. However, free 
Table 1 An overview of steroid hormones that have been associated with the prostate cancer, including steroids of the classical, 
alternative and backdoor pathways of DHT synthesis.
Steroid hormone Alternative names Molecular weight Conversion factor
11-deoxycorticosterone DOC 330.46 3.03
11-deoxycortisol S 346.46 2.89
17-hydroxy-allopregnanolone 334.49 2.99
17-hydroxy-pregnenolone 17OH-Preg 332.48 3.01
17-hydroxy-progesterone 17OH-Prog 330.46 3.03
5α-dihydrotestosterone DHT 290.44 3.44
5α-pregnan-17-ol-3,20-dione   332.48 3.01
5α-pregnane-3,20-dione 5α-progesterone 316.48 3.16
Androstanediol-glucoronide ADG 468.59 2.13
Aldosterone   360.45 2.77
Allopregnanolone   318.49 3.14
Androstanediol 3α-androstanediol 292.46 3.42
Androstanedione 5α-dione 288.42 3.47
Androstenediol   290.44 3.44
Androstenedione Δ4-dione, adione 286.4 3.49
Androsterone   290.44 3.44
Corticosterone B 346.47 2.89
Cortisol hydrocortisone 362.46 2.76
Dehydroepiandrosterone DHEA 288.42 3.47
Dehydroepiandrosterone-sulfate DHEAS 368.49 2.71
17b-estradiol E2 272.39 3.67
Pregnenolone   316.48 3.16
Progesterone   314.46 3.18
Testosterone T 288.42 3.47
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testosterone concentrations remain normal in moderately 
obese subjects (BMI < 35) due to the concurrent decline 
in SHBG (Giagulli et al. 1994, Saboor Aftab et al. 2013). 
Importantly, the elderly male population displays a 
high prevalence of chronic diseases. The presence of 
comorbidity is also accompanied by lower testosterone 
levels (Ahern et al. 2016).
Several studies comparing healthy to benign 
prostatic hyperplasia (BPH) subjects have reported equal 
testosterone levels, with mean values varying around 
15 nM (Hammond et  al. 1978, Heracek et  al. 2007a, 
Grosman et  al. 2010). Similarly, multiple studies report 
serum testosterone levels in subjects with localized PC 
that are on par with healthy controls (Gann et al. 1996, 
Figure 2
Serum steroid concentrations in healthy men and patients with prostate cancer during different modalities of treatment. The symbols depict the median 
of reported values from literature. A complete overview of papers reporting serum values for these steroids is available in Supplementary Table 1. 
Interquartile range data are presented when a full circle symbol is used. A semi-full circle depicts 95% confidence interval data. An open circle depicts 
range data. A semi-full diamond depicts a range of mean values from literature. Values from the recent McKay et al. (2017) study are listed 
independently because they achieved lower limits of quantification than other studies. *levels at or below the lower limit of quantification in the 
original study. The y-axis steroid values are spaced logarithmically. ADT, androgen deprivation therapy; BPH, benign prostatic hyperplasia; CRPC, 
castration-resistant prostate cancer; DHEA, dehydroepiandrosterone; DHEAS, dehydroepiandrosterone-sulfate; DHT, 5α-dihydrotestosterone.
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Endogenous Hormones and Prostate Cancer Collaborative 
Group 2008, Schenk et  al. 2016). Serum testosterone 
values did not appear to predict the incidence of 
prostate cancer (Daniels et al. 2010, Schenk et al. 2016). 
In contrast, no large differences were observed between 
aggressive (Gleason ≥ 7) and indolent tumors (Gleason < 7) 
(Severi et al. 2006, Muller et al. 2012).
After orchiectomy or ADT, intended to lower serum 
testosterone below ‘castrate levels’, serum testosterone 
levels change dramatically. The established cut-off for 
castrate serum testosterone levels is currently 1.73 nM 
(50 ng/dL). However, many studies report mean levels 
far below this limit using both immunoassays and 
LC–MS/MS, usually ≤0.5 nM (Rohl & Beuke 1992, Ishizaki 
et al. 2012, Hara et al. 2012, 2013, Mostaghel et al. 2014). 
This is slightly lower than the EC50 for AR activation of 
0.63 nM reported in literature (Sonneveld et al. 2005) and 
near the significant effect threshold (0.3 nM) observed 
in another study (Campana et  al. 2016). Testosterone 
levels of orchiectomized and ADT-treated subjects 
were comparable, although a statistically significant 
difference was observed in a study employing sensitive 
isotope dilution LC–MS/MS in 66 subjects (orchiectomy: 
0.319 nM; ADT: 0.138 nM) (van der Sluis et  al. 2012). 
Another study compared serum testosterone levels in 
ADT-responsive, ADT-nonresponsive and CRPC patients 
after treatment with combined androgen block but did 
not observe significant differences with mean levels of 
0.52, 0.38 and 0.31 nM, respectively. Despite the clear 
effect of ADT on serum testosterone levels, intratumoral 
testosterone levels in CRPC tissues are similar (2.78 nM 
vs 3.26 nM, respectively) (Mohler et al. 2004, Titus et al. 
2005) or even higher (Montgomery et al. 2008) compared 
to pre-castrate levels. Intratumoral testosterone levels 
are moderately reduced shortly after the initiation of 
LHRH antagonist treatment, as measured by LC–MS/MS 
(Shaw et al. 2016), suggesting intratumoral compensatory 
mechanisms during long-term ADT.
Finally, serum testosterone levels can be decreased to 
a greater extent, in a range that can only be measured 
reliably with LC–MS/MS, by abiraterone treatment. In one 
trial, median serum testosterone in CRPC patients declined 
from 0.35 nM at baseline to 0.02 nM after 12  weeks 
treatment with 1000 mg abiraterone and 5 mg prednisone 
daily (McKay et al. 2017). This is lower than the in vitro 
activation thresholds observed in literature, although 
intracellular levels may differ (Sonneveld et  al. 2005, 
Campana et  al. 2016). Equally low serum testosterone 
levels were detected in two other studies (Attard et al. 2008, 
Ryan et al. 2014) while a milder reduction was observed in 
a study that compared ketoconazole-progressive patients 
with abiraterone treatment (Kim et al. 2014).
A single study reported on post-enzalutamide levels in 
the neo-adjuvant setting. After 180 days of enzalutamide-
only treatment, serum and intratumoral testosterone 
levels were significantly increased when compared to 
both baseline and combination treatment consisting of 
enzalutamide, dutasteride and androgen deprivation 
therapy (Montgomery et  al. 2017). This is likely due to 
augmented hypothalamic–pituitary–gonadal axis activity 
following ablation of negative feedback by enzalutamide. 
The additive effects of enzalutamide on local or circulating 
androgen levels including testosterone in the castrate 
setting are unknown.
5α-dihydrotestosterone (DHT)
As the most potent natural androgen, DHT constitutes an 
essential target for the treatment of prostate cancer. DHT 
is synthesized within prostate cells from testosterone by 
the 5α-reductases, but is also present in serum. In control 
subjects, mean and median values between 1.2 and 2.0 nM 
have been reported by several studies, including one study 
employing LC–MS/MS (Hammond et al. 1978, Gann et al. 
1996, Yamashita et al. 2009, Trifiro et al. 2010, Stanczyk 
et  al. 2013). Similar values were observed in control 
subjects in the meta-study of the EHPCCG (Endogenous 
Hormones and Prostate Cancer Collaborative Group 
2008), with interquartile ranges varying between 0.91 
and 2.52 nM across 7 reviewed studies. A slightly higher 
mean serum DHT concentration of 3.22 nM was observed 
by Belanger and coworkers, which could reflect the 
occurrence of cross-reactivity in their radioimmunoassay 
(Belanger et al. 1994, Yarrow et al. 2013, Krasowski et al. 
2014).
In BPH subjects, reported values were quite similar 
(Hammond et  al. 1978, Heracek et  al. 2007a) although 
a small but statistically significant difference was 
detected in a follow-up study comparing men who did 
not develop BPH (1.44 nM) compared to men who did 
(1.65 nM) (Parsons et al. 2010). DHT levels can be strongly 
reduced with the 5α-reductase inhibitors finasteride and 
dutasteride. This has been tested in BPH patients, resulting 
in serum DHT levels below 0.03 nM, measured by mass 
spectrometry, after 24 weeks of treatment with 2.5–5 mg 
of dutasteride per day (Clark et al. 2004).
Determined by both RIA and LC–MS/MS, mean serum 
DHT levels in PC patients before castration are similar 
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to healthy controls (Hammond et al. 1978, Endogenous 
Hormones and Prostate Cancer Collaborative Group 2008, 
Miyoshi et  al. 2014) but can be reduced to 0.1–0.5 nM 
(mean) by either orchiectomy (Rohl & Beuke 1992) or 
ADT (Hara et al. 2013, Mostaghel et al. 2014, Taplin et al. 
2014). Even lower levels (<0.086 nM and <0.44 nM) were 
achieved in two studies using LC–MS/MS (Kim et al. 2014, 
McKay et al. 2017) in which CRPC patients were treated 
with abiraterone and prednisone. DHT concentrations 
necessary to activate the AR in vitro are estimated to be 
between 0.05 and 0.5 nM, and in some mammalian-
cell-based luciferase assays EC50 values as low as 0.01 nM 
were measured (Sonneveld et al. 2005, Dennis et al. 2008, 
Campana et al. 2016, Lallous et al. 2016). As such, values 
detected in castrated patients appear to approximate 
the EC50 values. DHT values in some abiraterone-treated 
patients were lower than 0.086 nM in one study but could 
not be assessed more accurately because they reached the 
lower limits of quantification (Kim et al. 2014). Therefore, 
it remains unclear whether abiraterone lowers serum DHT 
concentration below the AR activation limits. In contrast 
to abiraterone, enzalutamide in the neoadjuvant setting 
increased circulating DHT levels compared to baseline 
(Montgomery et al. 2017).
Androstenedione
Serum concentrations of the androgen precursor 
androstenedione are generally lower than testosterone 
levels in men, with several studies reporting mean values 
between 2.95 and 4.7 nM (Belanger et al. 1994, Severi et al. 
2006, Stanczyk et al. 2013, Tsilidis et al. 2015). This is in 
line with the findings of the EHPCCG, who report IQR 
values between 2.07 and 7.80 nM (Endogenous Hormones 
and Prostate Cancer Collaborative Group 2008).
Circulating androstenedione levels appear to be 
relatively similar in both BPH (Hammond et  al. 1978) 
and PC subjects (Hammond et  al. 1978, Chen et  al. 
2003, Severi et  al. 2006, Endogenous Hormones and 
Prostate Cancer Collaborative Group 2008). Unlike 
testosterone and DHT, serum androstenedione levels 
are not dramatically affected by either orchiectomy 
or ADT (Ayub & Levell 1990, van der Sluis et  al. 2012, 
Mostaghel et al. 2014). One study detected a mild albeit 
statistically significant decrease in androstenedione 
levels (5.58–2.89 nM after ADT), although still within 
the ranges reported by other studies (Hara et  al. 2013). 
This is in agreement with the adrenal cortex being the 
predominant source of androstenedione in men and with 
the adrenal cortex contributing to ongoing AR activation 
within PC cells after castration. Similar to testosterone and 
DHT, neoadjuvant enzalutamide treatment also increased 
serum androstenedione levels (Montgomery et al. 2017).
In contrast, abiraterone dramatically lowers serum 
androstenedione levels in CRPC patients, since CYP17A1 
catalyzes key steps in the synthesis of androstenedione. 
Mean values between 0.011 and 0.27 nM have been 
reported using LC–MS/MS in CRPC patients after 
12–24  weeks of abiraterone and prednisone treatment 
(Attard et  al. 2012, Mostaghel et  al. 2014, Taplin et  al. 
2014). Circulating androstenedione levels in untreated 
men are around or below the EC50 values for AR activation 
observed in vitro, which vary from 5.01 nM to 70 nM (Chen 
et al. 2004b, Sonneveld et al. 2005). As such, it is unlikely 
that androstenedione in itself is a major contributor to AR 
activation in prostate cancer, especially after suppression 
by abiraterone.
DHEA
DHEA is an important precursor of androstenedione and 
testosterone, although much of it circulates in the form 
of its inactive sulfate ester, DHEAS. Serum DHEA levels 
decline strongly with age and mean concentrations are 
4.03–9.07 nM in subjects aged 50–80 years (Belanger et al. 
1994), a process commonly referred to as adrenopause, 
which is slightly inaccurate as glucocorticoids and 
mineralocorticoids do not decline with age. In vitro data 
suggest that the required DHEA concentration to activate 
the AR is above 100 nM (Mizokami et al. 2004), meaning 
that DHEA is unlikely to contribute to AR activation at 
any stage in vivo. DHEA levels appear normal in subjects 
with localized PC (Nishiyama et  al. 2007, Taplin et  al. 
2014), although this is difficult to judge because of small 
sample sizes and the large differences between studies, 
as well as the high intra-individual variability of serum 
levels, despite the use of LC–MS/MS (Taplin et al. 2014; 
range: 0.08–20.57 nM). DHEA levels were also not 
significantly affected by ADT or ADT in combination 
with other anti-hormonal agents (Mostaghel et al. 2014). 
Again, treatment with enzalutamide in the neoadjuvant 
setting significantly stimulated serum DHEA levels 
(Montgomery et al. 2017).
Like androstenedione, serum DHEA levels are reduced 
upon treatment with abiraterone with reported values 
between 0.08 and 2.7 nM in several LC–MS/MS studies 
(Attard et al. 2008, Taplin et al. 2014, McKay et al. 2017). 
A  possible explanation for circulating DHEA levels not 
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being reduced as strongly as testosterone may be the 
continued presence of high (albeit diminished) levels of 
DHEAS after abiraterone treatment.
DHEAS
Serum DHEAS levels are higher than those of all other 
androgenic steroids combined and it is the only one that 
circulates in the micromolar range. DHEAS is a not an 
AR agonist (Bjerregaard-Olesen et al. 2016), but it can be 
converted into more potent androgens after removal of 
the sulfate group by the enzyme steroid sulfatase (STS) 
and conversion by 3β-HSD and 17β-HSD. STS activity 
has no relevant impact on circulating DHEAS levels 
(Hammer et  al. 2005) but desulfation of DHEAS can 
occur in prostate cells (Purohit & Foster 2012). In control 
subjects, serum DHEAS mean and median values typically 
fall between 1.2 and 3.2 µM (Belanger et al. 1994, Severi 
et  al. 2006, Endogenous Hormones and Prostate Cancer 
Collaborative Group 2008), with reported IQRs between 
0.8 and 4.68 µM by the EHPCCG.
Slightly lower DHEAS values were observed in 
BPH (2.6 µM) and PC subjects (1.9 µM) compared to 
control subjects (4.3 µM) in one study, but sample size 
was limited (Mitamura et  al. 2003). Additionally, lower 
DHEAS levels were associated with an increased risk for 
aggressive PC (Severi et  al. 2006). The EHPCCG meta-
study did not detect the differences between control and 
PC subjects (Endogenous Hormones and Prostate Cancer 
Collaborative Group 2008).
Serum DHEAS levels appeared unaffected by 
orchiectomy and ADT in two LC–MS/MS studies (van der 
Sluis et  al. 2012, Taplin et  al. 2014), although Hara and 
coworkers observed a statistically significant 38% decrease 
in patients with localized PC after 6 months of ADT (Hara 
et  al. 2013). Reported DHEAS levels in CRPC subjects 
were lower in some studies, with mean values before 
abiraterone treatment around 0.55–1.0 µM (Attard et  al. 
2008, Ryan et al. 2014), although values in CRPC patients 
can vary wildly (Matsubara et al. 2014). In contrast to the 
studies of Attard and coworkers and Ryan and coworkers 
much higher pretreatment mean values (5.2–6.2 µM) were 
reported in another study employing LC–MS/MS (Taplin 
et al. 2014, Attard et al. 2008, Ryan et al. 2014). This may 
be due to population differences between these studies. 
The latter study included younger patients (median 
55 years) with localized disease, good performance status 
and no prior prostate cancer targeting treatment while the 
former studies included older (median for both studies: 
69 years) patients previously treated with – and progressed 
on – ADT and/or chemotherapy and were in some cases 
prescribed corticosteroids. In each of these studies, 
however, abiraterone treatment strongly reduced DHEAS 
levels by 80–90%, with on-treatment values between 
0.14 and 0.4 µM. Even lower post-abiraterone treatment 
levels (median <0.03 µM) have been reported using highly 
sensitive LC-ESI-MS/MS by McKay and coworkers after 
24 weeks of treatment (McKay et al. 2017). Importantly, 
not only abiraterone but also administration of 
prednisone contributes to this effect through attenuation 
of ACTH levels. As markers of adrenocortical function, 
pretreatment levels of DHEA, DHEAS and androstenedione 
are all predictive biomarkers for abiraterone efficacy in 
CRPC patients (Attard et  al. 2009). Serum testosterone, 
androstenedione and DHEAS also proved to be prognostic 
for overall survival in a cohort treated with abiraterone 
(Ryan et al. 2013a).
Estradiol
Although initially employed solely as treatment to 
reduce serum testosterone levels, interest in the role 
of endogenous estradiol (E2) has risen in recent years, 
especially as a possible factor in the development of 
prostate cancer. A shift from apoptosis-inducing estrogen 
receptor (ER)-β signaling to the growth-stimulatory effects 
of ER-α during PC evolution suggests a proliferative 
role of estrogens in advanced disease stages (Rahman 
et al. 2016). E2 levels are very low in male subjects, with 
reported mean concentrations for healthy control groups 
in the 82–234 pM range (Hammond et al. 1978, Hsing & 
Comstock 1993, Belanger et  al. 1994, Chen et  al. 2003, 
Severi et  al. 2006, Endogenous Hormones and Prostate 
Cancer Collaborative Group 2008, Grosman et  al. 
2010). Findings in the meta-study of the EHPCCG show 
that there is a high level of disparity between different 
studies, with IQR values ranging from 51–84 pM to 
173–296 pM. No differences in serum E2 levels were 
detected between control and BPH subjects (Hammond 
et al. 1978, Grosman et al. 2010).
Most studies comparing E2 concentrations in control 
and PC subjects did not find differences between these 
groups (Hsing & Comstock 1993, Severi et  al. 2006, 
Endogenous Hormones and Prostate Cancer Collaborative 
Group 2008, Daniels et  al. 2010), although a single 
study reported higher levels in the PC group (200.1 pM) 
compared to controls (156.4 pM) (Grosman et  al. 2010). 
Testosterone is converted into E2 by aromatase and, 
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consequently, targeting testosterone synthesis with ADT 
will also reduce serum E2 levels. Several studies observed 
this effect, where ADT was able to reduce mean serum E2 
to levels in the range of 4–33 pM (Kitahara et  al. 1999, 
Basaria et  al. 2002, Qin et  al. 2013). Qin and coworkers 
noted a small non-significant increase in E2 levels in PC 
patients who progressed on complete androgen block 
(CAB) therapy, which combines regular ADT with anti-
androgens and in some cases 5α-reductase inhibitors 
(Qin et al. 2013). Only one study reported serum E2 levels 
in abiraterone-treated CRPC patients. After 4  weeks of 
treatment, the median E2 level was further reduced from 
7.2 pM to 2.9 pM (Attard et al. 2008). Patients with higher 
pretreatment E2 levels were also more likely to experience 
a ≥50% PSA decline following abiraterone treatment 
(Attard et al. 2009).
Pregnenolone and progesterone
Pregnenolone is the common steroid hormone precursor 
and is synthesized from cholesterol by CYP11A1. 
Pregnenolone is not an attractive target for the treatment 
of prostate cancer because of potential side effects caused 
by glucocorticoid and mineralocorticoid deficiencies. 
Serum pregnenolone levels have not been investigated 
in great detail. The reported values in subjects with BPH 
or PC appear to be similar to those in healthy controls 
(1.5–2.5 nM) (Hammond et  al. 1977, 1978, Belanger 
et al. 1994). Elevated pregnenolone levels were observed 
in abiraterone-treated CRPC patients (16.3 nM, IQR 
9.85–27.77 nM) using LC–MS/MS, and it was also 
noted that patients with high serum abiraterone levels 
(>35 ng/mL) had higher pregnenolone levels than 
patients with low abiraterone concentrations (McKay 
et al. 2017). This can be explained by impaired conversion 
of pregnenolone to 17OH-pregnenolone because of 
CYP17A1 inhibition by abiraterone, resulting in the 
accumulation of the former steroid.
Progesterone is not often considered in the context 
of androgens and prostate cancer, despite its well-
characterized activation of AR mutants and the assumed 
protective role of the stromal progesterone receptor 
in BPH and PC development (Chen et  al. 2017). Serum 
concentrations in healthy male controls are slightly lower 
than those for pregnenolone, with reported means around 
0.5–0.75 nM (Hammond et al. 1978, Belanger et al. 1994).
Hammond and coworkers observed no clear 
differences in progesterone levels between controls 
and BPH or PC subjects, and Ayub and Levell observed 
no change in progesterone levels in PC patients treated 
with orchiectomy or ADT (Hammond et  al. 1978). 
However, they did observe higher mean values at baseline 
(1.53–1.83 nM) than Hammond and coworkers (Ayub & 
Levell 1990, Hammond et al. 1978). Since progesterone is 
subject to hydrolysis by CYP17A1, LC–MS/MS-measured 
serum progesterone levels were mildly increased in 
abiraterone-treated subjects (median 2.77 nM, IQR 
1.62–5.18 nM) (McKay et  al. 2017). Both pregnenolone 
and progesterone serum levels were increased by 
enzalutamide treatment in eugonadal setting, again 
suggesting increased hypothalamic–pituitary–gonadal 
axis activity. However, adjuvant combination treatment 
with enzalutamide, dutasteride and ADT does not result 
in an increase in pregnenolone and significantly lowers 
progesterone (Montgomery et al. 2017).
17OH-pregnenolone and 17OH-progesterone
Derived from pregnenolone, 17OH-pregnenolone is an 
intermediate in the production of androgens as it can 
be converted into DHEA by the 17,20-lyase activity of 
CYP17A1. Belanger and coworkers reported a mean serum 
17OH-pregnenolone of 2.01 nM in healthy controls, 
and a total range of 1.08–12.3 nM is reported elsewhere 
(Kushnir et al. 2006, Belanger et al. 1994).
17OH-pregnenolone levels are rarely reported in 
human subjects in the context of prostate cancer. Two 
small studies reported values for PC patients before and 
after treatment with estrogens, but 17OH-pregnenolone 
levels appeared to be unaffected (Hammond et al. 1977, 
Kitahara et al. 1999). Since abiraterone inhibits CYP17A1 
activity, it is likely that serum 17OH-pregnenolone levels 
will be impaired in patients taking this drug.
17OH-progesterone is the product of hydrolysis 
of progesterone by CYP17A1 and is a glucocorticoid 
precursor. Serum concentrations decline with age 
(Belanger et al. 1994) and reported concentrations are in 
the 0.75–4.2 nM range for healthy controls (Hammond 
et  al. 1978, Kushnir et  al. 2006). 17OH-progesterone 
levels are similar in BPH and PC subjects and appear to be 
unaffected by orchiectomy or ADT (Hammond et al. 1978, 
Ayub & Levell 1990). Unfortunately, data in abiraterone-
treated patients are not available.
Androsterone
Androsterone is an inactive metabolite of DHT, but 
can also be converted back to DHT through the actions 
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of 17β-HSD types 5 (AKR1C3), 6 (HSD17B6) and 10 
(HSD17B10). It is also an intermediate of the backdoor 
DHT synthesis pathway (Arlt et al. 2004, Auchus 2004). 
Mean serum values for healthy controls were found to be 
between 1.4 and 2.87 nM (Belanger et al. 1994), although 
a slightly lower range of 1–1.5 nM was observed elsewhere 
(Hammond et al. 1978).
This latter study also did not observe a difference 
between control and BPH or PC subjects. Two other 
recent studies using LC–MS/MS (Mostaghel et  al. 2014, 
Taplin et  al. 2014) report mean values for PC patients 
(0.49 and 0.28–0.34 nM, respectively) that are below the 
range reported by Hammond and coworkers (0.5–2.2 nM) 
(Hammond et al. 1978). This difference is likely due to the 
use of liquid chromatography/tandem mass spectrometry 
in the former studies, preventing assay cross-reactivity 
among steroid hormone measurements. ADT treatment 
reduced serum androsterone levels by approximately 50% 
in both of these studies, reaching levels between 0.16 and 
0.28 nM (Mostaghel et  al. 2014, Taplin et  al. 2014). The 
abiraterone-treated subjects in the study of Taplin and 
coworkers reached serum androsterone concentrations 
below their LC–MS/MS assay detection limit of 0.03 nM 
(Taplin et al. 2014).
3α-androstanediol
3α-androstanediol (5α-androstane-3α,17β-diol), a 
metabolite of DHT, is usually measured in its inactive 
glucuronidized metabolite, 3α-androstanediol-
glucuronide. Studies analyzed by the EHPCCG report 
median values between 5.7 and 14.5 nM, with IQRs 
ranging from 3.9 to 19.8 nM (Endogenous Hormones and 
Prostate Cancer Collaborative Group 2008). These levels 
have been confirmed in more recent studies (Wiren et al. 
2007, Schenk et al. 2016).
Glucocorticoids and precursors
This class of steroid hormones is not known for its 
causative role in prostate cancer, but the glucocorticoid 
receptor has been implicated in advanced stages of disease 
(Arora et al. 2013).
Recently, altered metabolism of cortisol by intratumoral 
11β-hydroxysteroid dehydrogenase type 2 loss has been 
discovered as a resistance mechanism to enzalutamide 
treatment (Li et  al. 2017). Levels of cortisol, the main 
effector glucocorticoid, adhere to a circadian rhythm with 
a peak during the morning (138–635 nM) and a steady 
decline until a nadir is reached during the night (Auchus 
et al. 2014). Cortisol and its precursor 11-deoxycortisol are 
conversion products of 17OH-progesterone and are thus 
dependent on CYP17A1 activity. It is not expected that 
cortisol levels are aberrant in BPH or PC patients. Indeed, 
mean morning cortisol concentrations of 536 and 509 nM 
were observed in patient with local and advanced prostate 
cancer, respectively (Heracek et al. 2007b).
Inhibition of cortisol production following abiraterone 
treatment without addition of glucocorticoids causes 
withdrawal of negative feedback at the hypothalamic and 
pituitary level and subsequently increases ACTH levels up 
to 6-fold. Hence, cortisol levels remain relatively constant 
at baseline, but responses to ACTH following a short 
synacthen test were invariably insufficient. Since ACTH 
subsequently drives the production of mineralocorticoids 
with hypertensive capabilities and possibly also adrenal 
androgens, abiraterone is co-administered with the 
glucocorticoid prednisone, which is now the standard 
care treatment (O’Donnell et  al. 2004, Attard et  al. 
2008). Indeed, mean cortisol levels declined from 
303.6–358.8 nM to 124.2–276 nM after 21  days of 
abiraterone and corticosteroid co-treatment. Interestingly, 
11-deoxycortisol levels were increased as a consequence 
of abiraterone treatment, from 0.867–2.60 nM to 
2.89–9.39 nM (Ryan et al. 2010), confirming inhibition of 
11β-hydroxylase in vivo (Yin & Hu 2014).
Glucocorticoids may also impose more direct effects 
on prostate cancer proliferation upon mutation of the 
androgen receptor. Treatment with hormonal therapy 
in CRPC patients positively selects for mutations in 
the AR ligand-binding domain, several of which can be 
activated by glucocorticoids (Carreira et al. 2014, Romanel 
et  al. 2015). This is very relevant to abiraterone-treated 
patients for two reasons. Firstly, abiraterone is commonly 
co-administered with the GR agonist prednisone and, 
secondly, abiraterone-treated patients have elevated 
corticosterone levels, which also has GR activity 
(discussed below).
Mineralocorticoids and precursors
Mineralocorticoids are not known to be effectors of 
prostate cancer signaling and proliferation. These steroids 
are involved in fluid and electrolyte homeostasis and thus 
do not appear to play a major role in the development 
of prostate cancer. However, abiraterone inhibits 
synthesis of downstream steroids, causing pregnenolone 
and progesterone levels to accumulate. Similar to 
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glucocorticoids, no fluctuations in mineralocorticoids 
have been described in BPH or ADT-treated PC patients.
In abiraterone-treated patients, a strong increase 
was observed in deoxycorticosterone (DOC) from 0.196 
to 2.07 nM (median) and in corticosterone from 3.83 to 
188.0 nM (median) (Attard et al. 2008). Although cortisol 
is the main glucocorticoid in humans, corticosterone also 
has glucocorticoid activity. Several papers have shown that 
the mineralocorticoid excess can be treated by addition of 
prednisone (5 mg daily) or dexamethasone (0.5 mg daily), 
which is why abiraterone is always co-administered 
with exogenous glucocorticoids (Attard et al. 2008, Ryan 
et al. 2010, Pia et al. 2013). Additional inhibition of the 
mineralocorticoid receptor can be accomplished by 
eplerenone, whereas spironolactone should be avoided 
due to its capability of AR activation (Richards et al. 2012). 
Although strong elevation of DOC and corticosterone was 
observed in the study by Ryan and coworkers aldosterone 
levels remained relatively stable (Ryan et al. 2010). This is 
likely due to effects of ACTH, which primarily stimulates 
the zona fasciculata rather than the zona glomerulosa, 
which produces aldosterone and contains aldosterone 
synthase (CYP11B2). Thus, the mineralocorticoid excess 
symptoms in abiraterone-treated patients are caused by 
the mineralocorticoid DOC.
Alternative pathways of androgen synthesis
In addition to the canonical pathway of DHT synthesis, 
involving gonadal-derived testosterone, alternative 
pathways have been proposed recently (Auchus 
2004, Chang et  al. 2011). It has been shown that 
androstenedione can be preferentially converted into 
5α-androstanedione by SRD5A1 (Chang et al. 2011), the 
isozyme that is upregulated in CRPC tissue (Titus et  al. 
2005). To our knowledge, there are no studies reporting 
circulating 5α-androstanedione levels in male subjects or 
patients with prostate cancer.
Alternatively, another mechanism involving 
5α-reduction of progesterone and synthesis of 
allopregnanolone may lead to the production DHT 
without involvement of canonical androgen pathway 
intermediates (Fukami et  al. 2013). In this pathway, 
allopregnanolone is metabolized with high efficiency 
into androsterone by CYP17A1 (Auchus 2004). Since 
abiraterone reduces levels of canonical androgens and 
leads to accumulation of progesterone metabolites, this 
pathway may be of particular interest in patients that 
progress on abiraterone. Indeed urinary steroid metabolite 
analysis in PC patients treated with abiraterone revealed 
augmented concentrations of backdoor pathway 
metabolites (Attard et al. 2012). However, serum values of 
backdoor pathway intermediates in this group or other PC 
patients in general are missing.
Finally, there is another class of 11-oxygenated C19 
steroids that may play an important role in prostate 
cancer that has previously been overlooked. After 
DHEAS, 11OH-androstenedione is the most prevalent 
androgen precursor produced by the adrenal cortex. It 
can be produced from androstenedione by CYP11B1, 
and although this steroid itself does not activate the AR, 
it can be converted into 11-keto variants of testosterone 
and DHT that are equally potent agonists of the AR (Swart 
& Storbeck 2015, Pretorius et al. 2016). Plasma levels of 
11OH-androstenedione and 11keto-testosterone have 
recently been investigated and shown to reach a high 
baseline and augmented post-ADT levels of above 100 nM 
(du Toit et  al. 2017). Notably, 11keto-DHT levels were 
in the 10–20 nM range before treatment and showed no 
decrease after ADT, suggesting significant AR activation 
potential. This is also reflected by prominent tissue levels 
of these 11-oxygenated C19 steroids (du Toit et al. 2017). 
Until recently, these steroids and their physiological role 
has been overlooked in the literature and an increasing 
number of studies now confirm these steroids as interesting 
targets for androgen-dependent diseases, including PC.
Discussion and future prospects
Improving our understanding of steroid hormones, their 
homeostasis and their involvement in prostate cancer 
pathogenesis has been a central feature of prostate cancer 
research for decades. Research has focused predominantly 
on the canonical AR ligands testosterone and DHT. Limited 
data are available on the adrenal derived androgens DHEA 
and androstenedione, but little is known about possible 
variations in upstream steroids. Similarly, data on steroids 
downstream of testosterone and DHT are scarce.
The recent paradigm shift in treatment of PC with novel 
second-line hormonal therapy also necessitates accurate 
studies into the effects of these drugs on circulating and 
intratumoral hormone levels. This should also include 
the effects of enzalutamide. Aberrant hormonal pathways 
have been identified, but it is clear that we still do not 
fully understand how resistance occurs in many patients. 
It is therefore important that more data are obtained from 
these subjects. Making use of LC–MS/MS technological 
advancement to detect very small changes and measure 
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steroids at increasingly lower limits of quantification will 
be key to progressing our knowledge.
Inter-study variation is a relevant drawback 
complicating comparisons between different studies. 
Within the EHPCCG meta-study alone, median and IQR 
values vary drastically on a study-to-study basis. A value 
fitting securely within the normal range of one study may 
be considered aberrant compared to the normal range 
of another study. Without access to all the potential 
confounders within each individual study, it is necessary 
to consider a broader ‘normal’ range. Then, however, it 
becomes important not to lose track of potential small 
differences between two distinct populations, even if 
these values both fit within the broader normal range. 
For example, considering the small difference in estradiol 
levels between ADT-sensitive and CRPC subjects observed 
within the study of Qin and coworkers, it is possible 
that both values fall within a broader range of ‘normal’ 
estradiol levels, but a subtle shift may still be informative 
(Qin et al 2013). Those subtle changes, rather than more 
drastic shifts, may play an important role in the occurrence 
of resistance pathways.
The exact relevance of such subtle changes becomes 
apparent in the context of in vitro AR activation assays 
(Mizokami et  al. 2004, Sonneveld et  al. 2005, Dennis 
et al. 2008, Campana et al. 2016). Serum testosterone and 
DHT levels in healthy subjects greatly surpass the EC50 
values required for AR activation. However, ADT lowers 
serum testosterone and DHT to levels near or below the 
EC50 values, and this is accompanied by a PSA decline 
in most castrate patients. Abiraterone is capable of 
further lowering testosterone levels below the activation 
threshold and lowering DHT levels to the EC50 threshold, 
subsequently accompanied by an additional decline in 
serum PSA (McKay et  al. 2017). Small changes within 
this range may therefore greatly affect activation of the 
androgen receptor.
Levels of androstenedione and DHEA do not 
appear to reach sufficient levels in vivo to significantly 
contribute to AR activation under castrate conditions. 
However, these steroids may contribute to an important 
phenomenon observed in patient biopsies: high 
intracellular concentrations of DHT and testosterone 
despite castration serum testosterone levels (Montgomery 
et  al. 2008, Mostaghel 2014, Taplin et  al. 2014). These 
concentrations are sufficient to fully activate the AR and 
consequently intracellular steroidogenesis constitutes an 
important factor in cancer progression after castration. 
Elucidating this process of intracellular steroidogenesis 
is an important aim for further investigations, but 
unfortunately, CRPC tissue samples are difficult to obtain.
Abiraterone strongly reduces intraprostatic DHEA, 
androstenedione and DHT levels (Taplin et  al. 2014) 
and may thus impair intracellular steroid hormone 
conversion. However, it is important to consider serum 
DHEAS levels, which are in the >100 nM range in 
abiraterone-treated patients (Taplin et  al. 2014). DHEAS 
remains an important potential depot for downstream 
androgens synthesis (Tamae et al. 2015) after abiraterone 
treatment, particularly since organic anion transporting 
polypeptides (OATPs) associated with DHEAS uptake 
appear to be upregulated after androgen deprivation, at 
least in vitro (Arakawa et al. 2012).
While the clinical benefits of enzalutamide in 
different settings are being studied thoroughly, the effects 
of enzalutamide on steroid metabolism have been rarely 
reported. Only a single study reported serum steroid levels 
after enzalutamide treatment in the neoadjuvant setting 
for patients with high-risk localized prostate cancer who 
are scheduled to undergo prostatectomy (Montgomery 
et al. 2017). This study shows that while enzalutamide is 
a direct AR antagonist, it does significantly affect serum 
steroid levels, including elevated levels of testosterone 
and DHT. As far as we know, serum steroid levels after 
enzalutamide in the CRPC setting have not been reported 
in literature thus far, which represents an obvious 
omission in our understanding of resistance in the CRPC 
patients on enzalutamide therapy.
Finally, the alternative DHT synthesis pathways 
and the 11-oxygenated C19 steroids are also important 
considerations for further investigations, especially in 
CRPC patients. Hopefully, future studies will be able to 
elucidate the mechanisms of intracellular steroidogenesis 
and reveal its contribution in the castrate, abiraterone and 
post-abiraterone setting. Currently, little is known about 
the effects of the hormonal therapies on the levels of 
11-oxygenated C19 steroids.
For a long time CRPC has been considered androgen-
independent (Nelson et  al. 2003). Recent preclinical 
developments and the successful introduction of 
2nd-line hormonal treatment after castration have 
firmly established the relevance of residual presence of 
intratumoral androgens. Even following abiraterone 
treatment, steroid hormones can still significantly affect 
AR activation. Consequently, circulating steroid hormone 
levels continue to require clinical consideration and offer 
relevant targets for optimization or improvement of 
treatment of patients with advanced PC.
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